Lipe & Dalton’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Lipe & Dalton’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,968	Closed	-$430K	–	84
2017 Q4	$430K	Sell	7,968 -112	-1%	-$6.13K	0.3%	45
2017 Q3	$461K	Sell	8,080 -75	-0.9%	-$4.39K	0.32%	43
2017 Q2	$491K	Sell	8,155 -57	-0.7%	-$3.25K	0.32%	47
2017 Q1	$447K	Buy	+8,212	New	+$404K	0.32%	45

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Lipe & Dalton's BIVV Position: Q1 2018 in Review

Lipe & Dalton sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 7,968 shares — an estimated $430K sold.

Lipe & Dalton first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $491K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Lipe & Dalton reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Lipe & Dalton sold 7,968 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $430K.
Lipe & Dalton first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Lipe & Dalton's Bioverativ Inc. Common Stock position peaked at $491K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Lipe & Dalton's 13F filing for Q1 2018, filed 4 May 2018.